The Netherlands Cancer Institute (NKI) will deploy a diagnostic platform from digital and computational pathology solutions provider Proscia, the company announced.
Researchers generated human mini bones in the lab which mirror the composition and function of human bone - a step toward the development of future patient-tailored models of bone cancers and tumors.
Swedish researchers have developed a method that should be able to predict whether a patient with breast cancer will benefit from a particular treatment or not.
It is the size of a common pencil eraser, but it could have a huge impact on the therapy of glioblastoma: Scientists in Virginia have developed a novel 3D tissue-engineered model of the brain tumour microenvironment, which can be used to assess how the glioma cell invades healthy tissue, proliferates, and reacts to chemotherapy drugs.
Bowel cancer patients could in future benefit from a new 3D bioprinting technology which would use their own cells to replicate the complex cellular environment of solid tumours in 3D models.
Researchers from the University of Bern and Inselspital provide an overview of the latest technologies in precision oncology. Translating these into clinical application is still a major challenge.
It might sound like science fiction but it is reality in cardiology: with the help of artificial intelligence (AI) physicians can recognize from a patient’s headshot whether the person is suffering from coronary artery disease and is therefore at risk of myocardial infarction. But is that knowledge really useful? Professor Dr David Duncker calls for a differentiated and careful assessment of…
When every minute counts: A Swiss team is currently developing a diagnostic procedure that can be used to start a tailored therapy for acute stroke in a timely manner.
Personalised screening, data-driven aproaches: In a dedicated press conference in Paris, French oncologists presented promising research that might bring hope for many cancer patients.
Artificial intelligence (AI) could help guide the post-treatment surveillance of non-small cell lung cancer (NSCLC) patients and improve outcomes as a result, according to a new study.
Finding the right antibiotic dose is akin to a Goldilocks problem: give too little, and the infection will persist; too much, and side-effects will override the benefits of the therapy. To get it “just right”, Prof Dr Birgit Koch talks about dosing optimisation in the clinical setting.
Big data is transforming diagnosis and medical care, but the critical challenge remains over how to equally apply the benefits it delivers across real-world clinical settings, according to industry expert Prof Benoît Macq.
Molecular radiotherapy shows great potential in becoming a more mainstream treatment for cancer, but the field is being hampered by a limited radionuclide supply.
Mathematical models used as patient surrogates could help clinicians select the best cancer treatment before going to the patient’s bedside.
After a liver transplant, patients have to take immune-suppressing drugs for the rest of their lives. These so-called immunosuppressants prevent the organ from being rejected. However, the drugs increase the risk of cancer and serious infections. They can also significantly impair kidney function and even lead to dialysis. In order to be able to give those affected as much immunosuppression as…
A team led by the Garvan Institute of Medical Research has revealed a new approach for classifying breast cancer subtypes based on their cell profile, which could help personalise treatments for patients. By analysing breast cancer biopsies from patients at Sydney hospitals, the researchers revealed more than 50 distinct cancer, immune and connective cell types and states, which could assign…
A solid diagnosis has always been the first step on any patient’s journey to health. However, diagnostic categories are necessarily oversimplifications. In the last decades, medical professionals and scientists have begun to uncover the true variability in patients’ physiological and biochemical make-up that is the principal cause for individual variations in the way diseases present…
To avoid adverse reactions, personalised laboratory medicine can help to predict a patient’s drug response. Investigations based on DNA and other omics technologies – e.g. genomics, transcriptomics, proteomics, metabolomics – along with microarray technologies, is making a particularly valuable contribution to cancer care, in which personalised approaches are becoming possible through…
A new study from the University of Helsinki shows that cells that are freshly isolated from lung cancers can be used to create robust drug response data. This approach can identify actionable or non-responsive treatments, illustrated by a case study in which the assay was used to guide the compassionate treatment of a patient.
Cancer patients’ medical records can often comprise up to 100 terabytes of individual — and usually very heterogeneous — data, including blood and tumor values, personal indicators, sequencing and treatment data, and much more besides. Up to now, it has been virtually impossible to use this wealth of information efficiently due to a lack of appropriate processing mechanisms. As a result,…
El laboratorio de Genómica Biomédica del IRB Barcelona (Institute for Research in Biomedicine) ha desarrollado un método computacional que identifica las mutaciones causantes del cáncer para cada tipo de tumor.
The Biomedical Genomics laboratory at the Institute for Research in Biomedicine (IRB) Barcelona has developed a computational tool that identifies cancer driver mutations for each tumour type. This and other developments produced by the same lab seek to accelerate cancer research and provide tools to help oncologists choose the best treatment for each patient. The study has been published in the…
The Netherlands Cancer Institute, University of Amsterdam (UvA), and Elekta will collaborate on the development of new AI strategies for the further improvement of precision radiotherapy. This concerns the personalization of treatment by improving the quality of imaging used during treatment, predicting and accounting for changes in the patient’s anatomy over time, and automatically adapting…
Integrating laboratory functions on a microchip circuit is helping improve the cost-effectiveness of drug development. So-called ‘lab-on-a-chip’ or ‘human-on-a-chip’ technology can highlight which treatments may, or may not, work before advancing along the clinical trial process. It can also have benefits for chronic and rare diseases, as well as helping shape personalised medicine.…
Intrahepatic cholangiocarcinoma (ICC) develops within the liver. With one to two cases per 100,000 inhabitants in Germany, ICC is one of the rare diseases overall, but it is the second most common liver cancer. The aggressive bile duct tumour remains clinically inconspicuous for a long time, so that it is often only detected late. Because the tumour also only responds to chemotherapy to a limited…